Document is current
Any future updates will be listed below
-
Authors
Ogiya, Daisuke
Chyra, Zuzana
Verselis, Sigitas J.
O’Keefe, Morgan
Cobb, Jacquelyn
Abiatari, Ivane
Talluri, Srikanth
Sithara, Anjana Anilkumar
Hideshima, Teru
Chu, Michael P.
Hájek, Roman https://orcid.org/0000-0001-6955-6267
Dorfman, David M.
Pilarski, Linda M.
Anderson, Kenneth C. https://orcid.org/0000-0002-6418-0886
Adamia, Sophia https://orcid.org/0000-0001-5704-6040
-
Funding
Funding for this research was provided by:
The Paula and Rodger Riney Foundation (K.Anderson) The Adelson Medical Research Foundation
- License Information
-
More Information
Article History
Received: 27 January 2022
Revised: 17 December 2022
Accepted: 12 January 2023
First Online: 3 February 2023
Competing interests
: KCA is on the Advisory board of Celgene, Millenium-Takeda, Gilead, Janssen, Sanofi-Aventis, and Bristol Myers Squibb, and is a Scientific Founder of Oncopep and C4 Therapeutics. DC is a consultant to Stemline Therapeutic, Inc., Oncopeptide AB, and Equity owner in C4 Therapeutics. The remaining authors declare no competing interests.
